What does a low Lp(a) level indicate?

Low Lp(a) levels (below 30 mg/dL) are generally considered protective against cardiovascular disease and indicate a lower genetic risk for heart attacks and strokes. Unlike high Lp(a), which is a significant risk factor, low levels are typically not a health concern and may actually be beneficial for heart health.

Questions on this topic?Ask Sai, our AI longevity expert.
Ask Sai

Understanding Lp(a) and Its Role in Your Body

Lipoprotein(a), commonly abbreviated as Lp(a), is a unique type of cholesterol particle that plays a complex role in cardiovascular health. Unlike other cholesterol markers that fluctuate with diet and lifestyle, Lp(a) levels are primarily determined by genetics, with your levels remaining relatively stable throughout life after early childhood.

Lp(a) consists of an LDL-like particle attached to a protein called apolipoprotein(a). This structure makes it particularly sticky and prone to accumulating in artery walls, which is why elevated levels are associated with increased cardiovascular risk. However, when it comes to low Lp(a) levels, the story is quite different and generally positive for your health outlook.

What Are Considered Low Lp(a) Levels?

Medical professionals typically consider Lp(a) levels below 30 mg/dL (or 75 nmol/L) to be in the normal to low range. Some laboratories use different units of measurement, but the key threshold remains consistent: levels below this cutoff are associated with lower cardiovascular risk. Understanding your Lp(a) levels through comprehensive cardiovascular testing can provide valuable insights into your genetic risk profile.

Lp(a) Level Categories and Cardiovascular Risk

Lp(a) LevelRisk CategoryClinical SignificanceAction Required
<30 mg/dL<30 mg/dL (<75 nmol/L)Low/NormalProtective against CVDNo intervention needed
30-50 mg/dL30-50 mg/dL (75-125 nmol/L)BorderlineSlightly elevated riskMonitor other risk factors
>50 mg/dL>50 mg/dL (>125 nmol/L)HighSignificantly increased CVD riskAggressive risk factor management
>180 mg/dL>180 mg/dL (>430 nmol/L)Very High3-4x increased CVD riskConsider specialist referral

Lp(a) levels are measured in mg/dL or nmol/L. Risk categories are based on current cardiovascular guidelines.

It's important to note that there's no established 'too low' threshold for Lp(a). Unlike some biomarkers where both high and low levels can be problematic, research has not identified any health risks associated with very low or undetectable Lp(a) levels. In fact, some individuals have Lp(a) levels below 5 mg/dL, which is perfectly healthy.

How Lp(a) Levels Compare Across Populations

Lp(a) levels vary significantly across different ethnic populations due to genetic variations. African Americans tend to have higher average Lp(a) levels compared to Caucasians and Asians, though the cardiovascular risk associated with elevated levels appears to be similar across all populations. Understanding these population differences helps contextualize individual results.

The Cardiovascular Benefits of Low Lp(a)

Having low Lp(a) levels is generally considered protective against cardiovascular disease. Research has consistently shown that individuals with low Lp(a) have a reduced risk of several serious cardiovascular conditions, including coronary artery disease, heart attacks, strokes, and aortic valve stenosis.

This protective effect is particularly significant because Lp(a) is an independent risk factor for cardiovascular disease. This means that even if your other cholesterol markers (like LDL and HDL) are optimal, elevated Lp(a) can still increase your risk. Conversely, low Lp(a) provides an additional layer of cardiovascular protection beyond what's reflected in standard lipid panels.

Impact on Overall Cardiovascular Risk Assessment

When evaluating overall cardiovascular risk, low Lp(a) levels can help offset other risk factors. For instance, if you have slightly elevated LDL cholesterol or a family history of heart disease, having low Lp(a) may partially mitigate these risks. This is why comprehensive cardiovascular testing that includes Lp(a) provides a more complete picture of your heart health than traditional cholesterol tests alone.

Why Some People Have Low Lp(a) Levels

Lp(a) levels are determined almost entirely by genetics, specifically by variations in the LPA gene. The size and number of repeats in the apolipoprotein(a) component directly influence how much Lp(a) your liver produces. People with low Lp(a) typically have genetic variants that result in reduced production of this lipoprotein.

Unlike other cholesterol markers, lifestyle factors have minimal impact on Lp(a) levels. Diet, exercise, weight loss, and most cholesterol-lowering medications don't significantly affect Lp(a). This genetic determination means that if you have low Lp(a), you've essentially won a genetic lottery when it comes to this particular cardiovascular risk factor.

The Inheritance Pattern of Lp(a)

Lp(a) levels follow an autosomal codominant inheritance pattern, meaning you inherit one copy of the LPA gene from each parent. If both parents have low Lp(a) levels, their children are very likely to have low levels as well. This hereditary pattern makes family history an important consideration when interpreting Lp(a) results.

Clinical Implications of Low Lp(a)

From a clinical perspective, low Lp(a) levels require no treatment or intervention. Unlike high Lp(a), which may prompt more aggressive management of other cardiovascular risk factors, low levels are simply noted as a positive finding. Healthcare providers may use this information to refine risk stratification and potentially adjust treatment thresholds for other risk factors.

For individuals with low Lp(a), the focus remains on managing modifiable cardiovascular risk factors. This includes maintaining healthy cholesterol levels, blood pressure control, avoiding smoking, regular exercise, and a heart-healthy diet. While you can't change your Lp(a) levels, you can optimize other aspects of your cardiovascular health.

Testing and Monitoring Considerations

Since Lp(a) levels remain stable throughout adult life, most people only need to be tested once. However, certain life events or conditions may warrant retesting. These include significant hormonal changes (such as menopause), liver disease, or kidney disease, as these conditions can occasionally affect Lp(a) levels. Regular monitoring of your complete cardiovascular profile, including advanced markers like Lp(a), provides the most comprehensive view of your heart health.

When interpreting Lp(a) results, it's crucial to consider them in the context of your overall cardiovascular risk profile. This includes traditional risk factors like age, sex, smoking status, blood pressure, diabetes, and family history, as well as other lipid markers. A comprehensive approach to cardiovascular risk assessment provides the most accurate picture of your heart health.

Who Should Get Tested for Lp(a)?

Current guidelines recommend Lp(a) testing for individuals with a personal or family history of premature cardiovascular disease, those with familial hypercholesterolemia, individuals with recurrent cardiovascular events despite optimal treatment, and those being considered for PCSK9 inhibitor therapy. However, given the genetic nature of Lp(a) and its independent risk contribution, many experts advocate for universal screening at least once in adulthood.

The Bigger Picture: Lp(a) in Comprehensive Heart Health

While having low Lp(a) is certainly advantageous, it's essential to remember that cardiovascular health is multifaceted. Low Lp(a) doesn't guarantee protection from heart disease if other risk factors are present. Conversely, it provides valuable reassurance and may influence how aggressively other risk factors need to be managed.

Understanding your complete cardiovascular risk profile, including Lp(a) along with other advanced markers, empowers you to make informed decisions about your health. For those fortunate enough to have low Lp(a) levels, this genetic advantage is one less cardiovascular risk factor to worry about, allowing you to focus your prevention efforts on modifiable risk factors where you can make a meaningful impact.

References

  1. Tsimikas, S. (2017). A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69(6), 692-711.[Link][DOI]
  2. Kronenberg, F., & Utermann, G. (2013). Lipoprotein(a): resurrected by genetics. Journal of Internal Medicine, 273(1), 6-30.[Link][DOI]
  3. Nordestgaard, B. G., & Langsted, A. (2016). Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research, 57(11), 1953-1975.[Link][DOI]
  4. Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., et al. (2022). Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42(1), e48-e60.[Link][DOI]
  5. Kamstrup, P. R. (2021). Lipoprotein(a) and Cardiovascular Disease. Clinical Chemistry, 67(1), 154-166.[Link][DOI]

Was this article helpful?

Frequently Asked Questions

How can I test my Lp(a) at home?

You can test your Lp(a) at home with SiPhox Health's Heart & Metabolic Program, which includes Lp(a) testing along with comprehensive cardiovascular biomarkers. The Ultimate 360 Health Program also includes Lp(a) as part of its 50-biomarker panel for complete health optimization.

Is there such a thing as Lp(a) being too low?

No, there is no established 'too low' threshold for Lp(a). Research has not identified any health risks associated with very low or undetectable Lp(a) levels. Some people have levels below 5 mg/dL, which is perfectly healthy and may actually be protective against cardiovascular disease.

Can I lower my Lp(a) levels through diet or exercise?

Unfortunately, Lp(a) levels are primarily determined by genetics and are not significantly affected by lifestyle changes like diet or exercise. Unlike other cholesterol markers, Lp(a) remains relatively stable throughout life. Most cholesterol-lowering medications also have minimal impact on Lp(a) levels.

How often should I retest my Lp(a) levels?

Since Lp(a) levels remain stable throughout adult life, most people only need to be tested once. However, retesting may be warranted after significant hormonal changes (like menopause), or if you develop liver or kidney disease, as these conditions can occasionally affect Lp(a) levels.

If I have low Lp(a), am I protected from heart disease?

While low Lp(a) levels are protective and reduce your cardiovascular risk, they don't guarantee complete protection from heart disease. Other risk factors like high LDL cholesterol, high blood pressure, smoking, and diabetes still need to be managed. Low Lp(a) is one positive factor in your overall cardiovascular risk profile.

This article is licensed under CC BY 4.0. You are free to share and adapt this material with attribution.

Ask Questions About Any Health Topic

Chat with Sai, our AI health assistant, for personalized insights.

Click or drag file to upload blood test results

Backed By Leading Experts in Health Optimization

Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details